StreetInsider.com News Articles

Lake Street Starts Kyntra Bio (KYNB) at Buy

Thu, 17 Sep 2026 07:47:01 -0400

Lake Street analyst Daniel Brims initiates coverage on Kyntra Bio (NASDAQ: KYNB) with a Buy rating and a price target of $41.00.

For an analyst ratings summary and ratings history on Kyntra Bio click here. For more ratings news on Kyntra Bio click here.

Shares of Kyntra Bio closed at $7.61 yesterday.

Oppenheimer Reiterates Outperform Rating on Kyntra Bio (KYNB)

Tue, 01 Sep 2026 03:56:42 -0400

Oppenheimer analyst Jay Olson reiterated an Outperform rating and $35.00 price target on Kyntra Bio (NASDAQ: KYNB).

The analyst comments "We're encouraged by the restructuring of KYNB's royalty financing agreement with NQ Project Phoebus which we view as the final major step to set forth the company's operating plan. KYNB reduced maximum aggregate royalty-related obligations from $125M to $65M in exchange for a $42.6M accelerated payment, eliminating approximately $60M of future payment obligations while retaining substantial future royalty economics. The transaction materially strengthens financial flexibility heading into several important catalysts, including planned initiation of the pivotal Ph3 roxadustat study in lower-risk

Oppenheimer says this biotech name offers an "attractive buying opportunity"

Mon, 17 Aug 2026 12:00:00 -0400

Investing.com - Shares of this San Francisco-based biopharmaceutical company have shed more than 23% so far this year.

In its second quarter, the firm posted total assets of $101.1 million, a 43% drop versus a year ago. Bloomberg consensus estimates stood at $106.2 million.

Known for specializing in the research, development, and commercialization of novel biotherapeutic treatments focusing on oncology and rare diseases, Kyntra also posted net income from continuing operations of $12.0 million, or $2.96 net income per basic and diluted share, compared to a net loss of $13.7 million, or $3.38 net loss per basic and diluted share, one year

Kyntra Bio, Inc. (KYNB) Tops Q2 EPS by 614c

Thu, 13 Aug 2026 16:10:21 -0400

Kyntra Bio, Inc. (NASDAQ: KYNB) reported Q2 EPS of $2.96, $6.14 better than the analyst estimate of ($3.18).

For earnings history and earnings-related data on Kyntra Bio, Inc. (KYNB) click here.

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 16:02:00 -0400

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on track for 4Q 2026
Phase 3 protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden (HTB) has been finalized with the goal to initiate the registrational study in 4Q 2026
Additional data from the Phase 3 MATTERHORN study were presented at the European Hematology Association (EHA) Congress 2026, highlighting improvements in transfusion independence in patients with HTB and regardless of ring sideroblast status
Cash, cash

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 16:02:00 -0400

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on track for 4Q 2026

Phase 3 protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden (HTB) has been finalized with the goal to initiate the registrational study in 4Q 2026

Additional data from the Phase 3 MATTERHORN study were presented at the European Hematology Association (EHA) Congress 2026, highlighting improvements in transfusion independence in patients with HTB and regardless of ring sideroblast status

Cash, cash

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 16:02:00 -0400

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on track for 4Q 2026

Phase 3 protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden (HTB) has been finalized with the goal to initiate the registrational study in 4Q 2026

Additional data from the Phase 3 MATTERHORN study were presented at the European Hematology Association (EHA) Congress 2026, highlighting improvements in transfusion independence in patients with HTB and regardless of ring sideroblast status

Cash, cash

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 16:02:00 -0400

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on track for 4Q 2026

Phase 3 protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden (HTB) has been finalized with the goal to initiate the registrational study in 4Q 2026

Additional data from the Phase 3 MATTERHORN study were presented at the European Hematology Association (EHA) Congress 2026, highlighting improvements in transfusion independence in patients with HTB and regardless of ring sideroblast status

Cash, cash

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 16:02:00 -0400

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on track for 4Q 2026

Phase 3 protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden (HTB) has been finalized with the goal to initiate the registrational study in 4Q 2026

Additional data from the Phase 3 MATTERHORN study were presented at the European Hematology Association (EHA) Congress 2026, highlighting improvements in transfusion independence in patients with HTB and regardless of ring sideroblast status

Cash, cash

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 16:02:00 -0400

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on track for 4Q 2026

Phase 3 protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden (HTB) has been finalized with the goal to initiate the registrational study in 4Q 2026

Additional data from the Phase 3 MATTERHORN study were presented at the European Hematology Association (EHA) Congress 2026, highlighting improvements in transfusion independence in patients with HTB and regardless of ring sideroblast status

Cash, cash

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 16:02:00 -0400

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on track for 4Q 2026

Phase 3 protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden (HTB) has been finalized with the goal to initiate the registrational study in 4Q 2026

Additional data from the Phase 3 MATTERHORN study were presented at the European Hematology Association (EHA) Congress 2026, highlighting improvements in transfusion independence in patients with HTB and regardless of ring sideroblast status

Cash, cash

Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 16:02:00 -0400

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on track for 4Q 2026

Phase 3 protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden (HTB) has been finalized with the goal to initiate the registrational study in 4Q 2026

Additional data from the Phase 3 MATTERHORN study were presented at the European Hematology Association (EHA) Congress 2026, highlighting improvements in transfusion independence in patients with HTB and regardless of ring sideroblast status

Cash, cash

Kyntra Bio to Report Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 09:00:00 -0400

SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce second quarter 2026 financial results on Thursday, August 13 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Conference Call and Webcast Presentation
Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio

Kyntra Bio to Report Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 09:00:00 -0400

SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce second quarter 2026 financial results on Thursday, August 13 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Conference Call and Webcast Presentation
Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio

Kyntra Bio to Report Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 09:00:00 -0400

SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce second quarter 2026 financial results on Thursday, August 13 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Conference Call and Webcast Presentation
Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio

Kyntra Bio to Report Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 09:00:00 -0400

SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce second quarter 2026 financial results on Thursday, August 13 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Conference Call and Webcast Presentation
Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio

Oppenheimer Starts Kyntra Bio (KYNB) at Outperform, PT $35

Mon, 06 Jul 2026 16:14:46 -0400

Oppenheimer analyst Jay Olson initiates coverage on Kyntra Bio (NASDAQ: KYNB) with a Outperform rating and a price target of $35.00.
The analyst comments "We initiate coverage of Kyntra Bio with an Outperform rating and $35 PT, given our optimism for lead programs FG-3246 and FG-3180 to address the persistent unmet need among ~65K US-based mCRPC patients, particularly in PSMA-low/-negative and post-ARPI settings. As the only CD46-directed ADC and the only non-PSMA ADC with a PET CDx (FG-3180), FG-3246 is uniquely positioned against the PSMA-dominated mCRPC pipeline, with potential to unlock value for KYNB on Ph2 monotherapy interim data in 4Q26.

Oppenheimer Starts Kyntra Bio (KYNB) at Outperform, PT $35

Mon, 06 Jul 2026 16:14:46 -0400

Oppenheimer analyst Jay Olson initiates coverage on Kyntra Bio (NASDAQ: KYNB) with a Outperform rating and a price target of $35.00.
The analyst comments "We initiate coverage of Kyntra Bio with an Outperform rating and $35 PT, given our optimism for lead programs FG-3246 and FG-3180 to address the persistent unmet need among ~65K US-based mCRPC patients, particularly in PSMA-low/-negative and post-ARPI settings. As the only CD46-directed ADC and the only non-PSMA ADC with a PET CDx (FG-3180), FG-3246 is uniquely positioned against the PSMA-dominated mCRPC pipeline, with potential to unlock value for KYNB on Ph2 monotherapy interim data in 4Q26.

Oppenheimer Starts Kyntra Bio (KYNB) at Outperform, PT $35

Mon, 06 Jul 2026 16:14:46 -0400

Oppenheimer analyst Jay Olson initiates coverage on Kyntra Bio (NASDAQ: KYNB) with a Outperform rating and a price target of $35.00.
The analyst comments "We initiate coverage of Kyntra Bio with an Outperform rating and $35 PT, given our optimism for lead programs FG-3246 and FG-3180 to address the persistent unmet need among ~65K US-based mCRPC patients, particularly in PSMA-low/-negative and post-ARPI settings. As the only CD46-directed ADC and the only non-PSMA ADC with a PET CDx (FG-3180), FG-3246 is uniquely positioned against the PSMA-dominated mCRPC pipeline, with potential to unlock value for KYNB on Ph2 monotherapy interim data in 4Q26.

Oppenheimer Starts Kyntra Bio (KYNB) at Outperform, PT $35

Mon, 06 Jul 2026 16:14:46 -0400

Oppenheimer analyst Jay Olson initiates coverage on Kyntra Bio (NASDAQ: KYNB) with a Outperform rating and a price target of $35.00.
The analyst comments "We initiate coverage of Kyntra Bio with an Outperform rating and $35 PT, given our optimism for lead programs FG-3246 and FG-3180 to address the persistent unmet need among ~65K US-based mCRPC patients, particularly in PSMA-low/-negative and post-ARPI settings. As the only CD46-directed ADC and the only non-PSMA ADC with a PET CDx (FG-3180), FG-3246 is uniquely positioned against the PSMA-dominated mCRPC pipeline, with potential to unlock value for KYNB on Ph2 monotherapy interim data in 4Q26.

Kyntra Bio presents roxadustat data showing transfusion improvements in MDS

Thu, 11 Jun 2026 16:06:22 -0400

Kyntra Bio (NASDAQ: KYNB) announced data from its Phase 3 MATTERHORN trial showing roxadustat improved transfusion independence in patients with lower-risk myelodysplastic syndromes and high transfusion burden. The data was presented at the European Hematology Association Congress in Stockholm.
In a post-hoc analysis of patients with high transfusion burden, defined as requiring at least 4 units of red blood cells per 8-week period for two consecutive periods, roxadustat demonstrated higher rates of transfusion independence compared to placebo across 8, 12, and 16-week periods. The analysis included 37 patients who met the high transfusion burden criteria from the 140 total trial participants.
The

Kyntra Bio presents roxadustat data showing transfusion improvements in MDS

Thu, 11 Jun 2026 16:06:22 -0400

Kyntra Bio (NASDAQ: KYNB) announced data from its Phase 3 MATTERHORN trial showing roxadustat improved transfusion independence in patients with lower-risk myelodysplastic syndromes and high transfusion burden. The data was presented at the European Hematology Association Congress in Stockholm.
In a post-hoc analysis of patients with high transfusion burden, defined as requiring at least 4 units of red blood cells per 8-week period for two consecutive periods, roxadustat demonstrated higher rates of transfusion independence compared to placebo across 8, 12, and 16-week periods. The analysis included 37 patients who met the high transfusion burden criteria from the 140 total trial participants.
The

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

Thu, 11 Jun 2026 16:05:00 -0400

In a post hoc analysis, patients treated with roxadustat showed a durable and clinically meaningful improvement in transfusion independence (TI) in patients with LR-MDS and high transfusion burden (HTB) compared to placebo

Similar rates of TI for patients treated with roxadustat were observed in both ring sideroblast positive (RS+) and ring sideroblast negative (RS-) disease

Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with LR-MDS and high transfusion burden is being finalized based on feedback received from the Food and Drug Administration (FDA)

SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE)

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

Thu, 11 Jun 2026 16:05:00 -0400

In a post hoc analysis, patients treated with roxadustat showed a durable and clinically meaningful improvement in transfusion independence (TI) in patients with LR-MDS and high transfusion burden (HTB) compared to placebo

Similar rates of TI for patients treated with roxadustat were observed in both ring sideroblast positive (RS+) and ring sideroblast negative (RS-) disease

Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with LR-MDS and high transfusion burden is being finalized based on feedback received from the Food and Drug Administration (FDA)

SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE)

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

Thu, 11 Jun 2026 16:05:00 -0400

In a post hoc analysis, patients treated with roxadustat showed a durable and clinically meaningful improvement in transfusion independence (TI) in patients with LR-MDS and high transfusion burden (HTB) compared to placebo

Similar rates of TI for patients treated with roxadustat were observed in both ring sideroblast positive (RS+) and ring sideroblast negative (RS-) disease

Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with LR-MDS and high transfusion burden is being finalized based on feedback received from the Food and Drug Administration (FDA)

SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE)